Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis

Kaisu Kotaniemi1,2, Hanna S&auml;il&auml;2, Hannu Kautiainen31Helsinki University Hospital, Helsinki, Finland; 2Orton Orthopaedic Hospital and Rehabilitation Unit, Helsinki, Finland; 3Unit of Primary Health Care, Kuopio University Hospital, Kuopio, FinlandBackground: The purpose of t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kotaniemi K, S&auml;il&auml; H, Kautiainen H
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/e273faab65c548fdaf1eaa0bae2d645c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e273faab65c548fdaf1eaa0bae2d645c
record_format	dspace
spelling	oai:doaj.org-article:e273faab65c548fdaf1eaa0bae2d645c2021-12-02T07:01:11ZLong-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis1177-54671177-5483https://doaj.org/article/e273faab65c548fdaf1eaa0bae2d645c2011-10-01T00:00:00Zhttp://www.dovepress.com/long-term-efficacy-of-adalimumab-in-the-treatment-of-uveitis-associate-a8397https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Kaisu Kotaniemi1,2, Hanna S&auml;il&auml;2, Hannu Kautiainen31Helsinki University Hospital, Helsinki, Finland; 2Orton Orthopaedic Hospital and Rehabilitation Unit, Helsinki, Finland; 3Unit of Primary Health Care, Kuopio University Hospital, Kuopio, FinlandBackground: The purpose of this study was to investigate the long-term effects of adalimumab, a tumor necrosis factor alpha antagonist, in the treatment of uveitis associated with juvenile idiopathic arthritis.Methods: Adalimumab was initiated in 94 patients with juvenile idiopathic arthritis to treat active arthritis and/or active associated uveitis. In 18 patients, therapy was discontinued after a short period because of inefficacy or side effects. The activity of uveitis (using Standardized Uveitis Nomenclature [SUN] criteria and clinical examination) and arthritis (number of swollen or active joints) was evaluated at the start and at end of the study.Results: At the end of the study, uveitis was under good clinical control in two thirds of 54 patients (31% did not need any local treatment and 35% used only 1&ndash;2 corticosteroid drops a day), and one third had active uveitis (at least three corticosteroid drops a day). According to SUN criteria, adalimumab treatment for uveitis showed improved activity (a two-fold decrease in uveitis activity) in 28% of patients, with a moderate response in 16 patients, no change in a further 16 patients, and worsening activity (a two-fold increase in uveitis activity) in 13% of patients. The overall proportion of patients with active arthritis decreased. At the beginning of the study, 69% of patients with uveitis had more than two active joints, and at the end of the study only 27% had active joint disease. In 27 patients with juvenile idiopathic arthritis without uveitis on adalimumab, the number of active joints decreased from 93% to 59%. Systemic corticosteroid treatment could be stopped in 22% of patients with uveitis and in 11% of those without uveitis. Most of the patients had received methotrexate, other immunosuppressive therapy, or other biological drugs before initiating adalimumab.Conclusion: Adalimumab is a valuable option in the treatment of uveitis associated with active juvenile idiopathic arthritis.Keywords: adalimumab, juvenile idiopathic arthritis, uveitisKotaniemi KS&auml;il&auml; HKautiainen HDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2011, Iss default, Pp 1425-1429 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Kotaniemi K S&auml;il&auml; H Kautiainen H Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis
description	Kaisu Kotaniemi1,2, Hanna S&auml;il&auml;2, Hannu Kautiainen31Helsinki University Hospital, Helsinki, Finland; 2Orton Orthopaedic Hospital and Rehabilitation Unit, Helsinki, Finland; 3Unit of Primary Health Care, Kuopio University Hospital, Kuopio, FinlandBackground: The purpose of this study was to investigate the long-term effects of adalimumab, a tumor necrosis factor alpha antagonist, in the treatment of uveitis associated with juvenile idiopathic arthritis.Methods: Adalimumab was initiated in 94 patients with juvenile idiopathic arthritis to treat active arthritis and/or active associated uveitis. In 18 patients, therapy was discontinued after a short period because of inefficacy or side effects. The activity of uveitis (using Standardized Uveitis Nomenclature [SUN] criteria and clinical examination) and arthritis (number of swollen or active joints) was evaluated at the start and at end of the study.Results: At the end of the study, uveitis was under good clinical control in two thirds of 54 patients (31% did not need any local treatment and 35% used only 1&ndash;2 corticosteroid drops a day), and one third had active uveitis (at least three corticosteroid drops a day). According to SUN criteria, adalimumab treatment for uveitis showed improved activity (a two-fold decrease in uveitis activity) in 28% of patients, with a moderate response in 16 patients, no change in a further 16 patients, and worsening activity (a two-fold increase in uveitis activity) in 13% of patients. The overall proportion of patients with active arthritis decreased. At the beginning of the study, 69% of patients with uveitis had more than two active joints, and at the end of the study only 27% had active joint disease. In 27 patients with juvenile idiopathic arthritis without uveitis on adalimumab, the number of active joints decreased from 93% to 59%. Systemic corticosteroid treatment could be stopped in 22% of patients with uveitis and in 11% of those without uveitis. Most of the patients had received methotrexate, other immunosuppressive therapy, or other biological drugs before initiating adalimumab.Conclusion: Adalimumab is a valuable option in the treatment of uveitis associated with active juvenile idiopathic arthritis.Keywords: adalimumab, juvenile idiopathic arthritis, uveitis
format	article
author	Kotaniemi K S&auml;il&auml; H Kautiainen H
author_facet	Kotaniemi K S&auml;il&auml; H Kautiainen H
author_sort	Kotaniemi K
title	Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis
title_short	Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis
title_full	Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis
title_fullStr	Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis
title_full_unstemmed	Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis
title_sort	long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/e273faab65c548fdaf1eaa0bae2d645c
work_keys_str_mv	AT kotaniemik longtermefficacyofadalimumabinthetreatmentofuveitisassociatedwithjuvenileidiopathicarthritis AT sampaumlilampaumlh longtermefficacyofadalimumabinthetreatmentofuveitisassociatedwithjuvenileidiopathicarthritis AT kautiainenh longtermefficacyofadalimumabinthetreatmentofuveitisassociatedwithjuvenileidiopathicarthritis
_version_	1718399667242270720

Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis

Ejemplares similares